Pacira BioSciences, Inc.
PCRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M |
| Operating income | $19.2M | −$73.4M | $87.7M | $60.0M | $89.9M | $46.4M |
| Net income | $7.0M | −$99.6M | $42.0M | $15.9M | $42.0M | $145.5M |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.34B | $654.8M |
| Equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M | $619.7M |
| EPS (diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 |
| Shares out. | 46.3M | 46.5M | 46.0M | 44.8M | 43.9M | 42.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 2.6%
- Net margin
- 1.0%
- Return on equity
- 1.0%
- Return on assets
- 0.6%
- Return on capital (ROCE)
- 1.7%
- Liabilities / assets
- 45.2%
- Debt / equity
- 0.82×
- Book value / share
- $14.98
- Revenue growth (YoY)
- 3.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.08safe
- Accruals / assets
- −11.5%clean
- Beneish M-Score
- -2.94normal
- Piotroski F-Score
- 9/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)May 1, 2026
- Vanguard Capital Management LlcPassive (13G)May 1, 2026
- Dimensional Fund Advisors LpPassive (13G)Apr 9, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Doma Perpetual Capital Management LlcActivist (13D)Mar 12, 2026
- Renaissance Technologies LlcPassive (13G)Nov 13, 2025
- Pacer Advisors, Inc.Passive (13G)May 2, 2025
- Blackrock, Inc.Passive (13G)Apr 28, 2025
- Millennium Management LlcPassive (13G)Apr 21, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.0M | 10.3 | -10.3% |
| Apr 30, 2026 | 7.8M | 14.2 | +5.4% |
| Apr 15, 2026 | 7.4M | 15.7 | -8.3% |
| Mar 31, 2026 | 8.1M | 10.1 | -4.6% |
| Mar 13, 2026 | 8.4M | 10.1 | -0.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 30, 2026
- Results of operationsFeb 26, 2026
- Director / officer change · Regulation FD disclosureJan 28, 2026
- Results of operationsJan 8, 2026
- Results of operationsNov 6, 2025
- Results of operationsAug 5, 2025
- Costs from exit or disposal · Regulation FD disclosureJul 10, 2025
- Entered a material agreement · Terminated a material agreement · New financial obligationJul 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.